Transplant Ineligible Multiple Myeloma: Updates to the MAIA Study

Peter Voorhees, MD, provides a broad overview on risk assessment and the goals of therapy in multiple myeloma management.

Expert insight on the optimal management of transplant-ineligible newly diagnosed multiple myeloma in light of available therapies and clinical data.

Updated results from the MAIA trial, which tested the addition of daratumumab to lenalidomide-dexamethasone therapy in patients with transplant-ineligible newly diagnosed multiple myeloma.

Peter Voorhees, MD, reflects on practical implications of the MAIA trial and how best to manage a patient with newly diagnosed multiple myeloma.

In the context of multiple myeloma, Peter Voorhees, MD, considers the role of doublet vs triplet therapy, initial therapy selection, and monitoring treatment response.

Considerations for future unmet needs and novel therapies in multiple myeloma, followed by practical advice for community oncologists.